501 related articles for article (PubMed ID: 16673210)
1. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals.
Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210
[TBL] [Abstract][Full Text] [Related]
2. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
Eri LM; Haug E; Tveter KJ
Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
[TBL] [Abstract][Full Text] [Related]
3. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
[TBL] [Abstract][Full Text] [Related]
4. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
6. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
[TBL] [Abstract][Full Text] [Related]
7. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
9. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
10. Puberty induction in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels.
Bannink EM; van Sassen C; van Buuren S; de Jong FH; Lequin M; Mulder PG; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2009 Feb; 70(2):265-73. PubMed ID: 19200215
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women.
Spinder T; Spijkstra JJ; Gooren LJ; Hompes PG; van Kessel H
J Clin Endocrinol Metab; 1989 Jan; 68(1):200-7. PubMed ID: 2491861
[TBL] [Abstract][Full Text] [Related]
12. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.
Nuver J; Smit AJ; Wolffenbuttel BH; Sluiter WJ; Hoekstra HJ; Sleijfer DT; Gietema JA
J Clin Oncol; 2005 Jun; 23(16):3718-25. PubMed ID: 15738540
[TBL] [Abstract][Full Text] [Related]
13. Body composition and bone mineral density in male-to-female transsexuals during cross-sex hormone therapy using gonadotrophin-releasing hormone agonist.
Mueller A; Zollver H; Kronawitter D; Oppelt PG; Claassen T; Hoffmann I; Beckmann MW; Dittrich R
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):95-100. PubMed ID: 20625973
[TBL] [Abstract][Full Text] [Related]
14. Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis.
Sathyapalan T; González S; Atkin SL
Climacteric; 2009 Oct; 12(5):427-30. PubMed ID: 19637056
[TBL] [Abstract][Full Text] [Related]
15. [Changes of serum testosterone-estradiol-binding globulin, follicular stimulating hormone, luteinizing hormone, estradiol, progesterone, and testosterone levels in women associated with aging].
Kamatsuki S
Igaku Kenkyu; 1982 Nov; 52(5):243-55. PubMed ID: 6821181
[No Abstract] [Full Text] [Related]
16. Short term changes in melatonin and cortisol serum levels after a single administration of estrogen to menopausal women.
Kerdelhué B; Andrews MC; Zhao Y; Scholler R; Jones HW
Neuro Endocrinol Lett; 2006 Oct; 27(5):659-64. PubMed ID: 17159819
[TBL] [Abstract][Full Text] [Related]
17. Testicular function in hyperthyroidism.
Hudson RW; Edwards AL
J Androl; 1992; 13(2):117-24. PubMed ID: 1597395
[TBL] [Abstract][Full Text] [Related]
18. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
19. The effect of circulating estradiol concentrations on gonadotropin secretion in young and old castrated male-to-female transsexuals.
Ten Kulve JS; de Jong FH; de Ronde W
Aging Male; 2011 Sep; 14(3):155-61. PubMed ID: 20828248
[TBL] [Abstract][Full Text] [Related]
20. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
